Moderna Therapeutics’ Stock Price Soared, Then Gave Back Its Gains in Two Consecutive Days To begin with, most, if not all, development-stage firms are yo-yo games played by day traders and investors whose strategies are buying low and selling high. These people also buy and sell on encouraging news and bad news; if their eyes happen to fall on any fundamental news.   One of …

Synopsis The way many bloggers are interpreting the quarterly and yearly biotech companies’ financial results seems unfair and has proven to be. Amgen Amgen (AMGN): The stock gained over $10 yesterday and is trading now at $231. Many bloggers continue to attack the firm, mourning the loss of their protective patents on its over 30 years’ old products and ignore the record . . . …

As the Market Seems to Soar Our Eyes Are on the Following Biotech Stocks: Amgen (AMGN): A rebounding is expected following an unwarranted decline.   Gilead Sciences (GILD): A lot of good news from the firm, including the firm’s investigational product remdesivir that demonstrated positive results in beating the coronavirus infection. Read yesterday's article posted

Regenxbio, Moderna and Others Regenxbio (RGNX) announced several poster presentations including interim data from its Phase I/II trial of RGX-121 for the treatment of Mucopolysaccharidosis Type II (MPS II

Coronavirus On January 7, 2020, a novel coronavirus (2019-nCoV) was identified in humans in Wuhan City, Hubei Province, China. Additional cases have been found in the United States and in a growing number of countries around the world.    Coronaviruses are a family of viruses that can lead to respiratory illness, including Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV). Coronaviruses are …